Evidence map›Paper›PMID 42091838›Full record

ArticleFolia microbiologica2026

Laser-ablated gold nanoparticles: a novel approach to antimicrobial artificial eyes.

Alaa Mohamed, Ahmed O El-Gendy, Khaled Salah Eldin Abdelkader, Esraa Ahmed, Tarek Mohamed, Mohamed Mobarak

Abstract read
PubMed Publisher
In one paragraph

Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alaa MohamedDepartment of Optics Technology, Faculty of Applied Health Sciences Technology, Beni-Suef University, Beni-Suef, 62511, Egypt.
Ahmed O El-GendyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62511, Egypt.
Khaled Salah Eldin AbdelkaderDepartment of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Esraa AhmedLaser Institute for Research and Applications LIRA, Beni-Suef University, Beni-Suef, 62511, Egypt.
Tarek MohamedLaser Institute for Research and Applications LIRA, Beni-Suef University, Beni-Suef, 62511, Egypt. tarek_mohamed1969@lira.bsu.edu.eg.
Mohamed MobarakPhysics Department, Faculty of Science, Beni-Suef University, Beni-Suef, 62511, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with artificial eyes often suffer from severe, persistent microbial infections, particularly due to antibiotic-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). Nowadays, gold nanoparticles (AuNPs) exhibit strong antimicrobial properties, offering a promising solution to this challenge. In this study, laser ablation was employed to create AuNPs, which were added into artificial eye materials during fabrication. The antimicrobial efficacy of laser-ablated AuNPs against resistant bacteria was systematically evaluated using multiple microbiological assays. A colony forming unit and growth kinetic analysis were determined using an ANOVA test. Moreover, Logistic and Gompertz models were performed to visualize the MRSA growth kinetic rate. Our findings show that AuNPs significantly reduce bacterial growth, suggesting their potential as an effective antimicrobial component in ocular prostheses. Theoretically, the Gompertz model was the best-fit model for experimental kinetic data. We have produced a foundational framework for integrating AuNPs into artificial eyes to combat infections, paving the way for the development of novel antimicrobial ocular prostheses.

Indexed as

And antimicrobial activityArtificial eyeGold nanoparticles (AuNPs)Laser ablationMRSA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.